Baron & Budd Secures $13.25 Million to Settle Texas Whistleblower Lawsuit Against Endo Pharmaceuticals for Fraudulently Marketing Lidoderm for Unapproved Uses
This case follows a 2014 settlement, in which Endo agreed to pay $192.7 million to federal and state governments to resolve a lawsuit which alleged that the company marketed Lidoderm for uses not approved as safe and effective by the FDA. The state of Texas opted out of the federal fraud litigation and chose to bring a separate action under Texas law. Classified as a whistleblower lawsuit, information to support the allegations of the fraud was brought forth by a former Endo sales representative, Max Weathersby, and two other individuals, under MK Litigation Partnership LLC, who had extensive and detailed information about the sales and marketing tactics of the drug.
“We often read headlines about cases where a drug does more harm than good, but as taxpayers paying for programs like Medicaid, we should be outraged at having to pay for a drug that does nothing at all to help the patient because that wastes precious resources,” said Scott Simmer, of the law firm Baron & Budd and the attorney representing the whistleblowers in the case. “In this case, our clients alleged that Endo deliberately chose to suppress the findings of five clinical trials it had sponsored, all of which showed Lidoderm was no more effective than a placebo for treating various types of pain.”
From 2002 to 2006, Lidoderm was approved by the FDA only for the relief of pain associated with shingles, a disease which the Centers for Disease Control says affects around one million Americans per year. Similar to the federal case, the suit brought by the State of Texas alleged that Endo deliberately chose to withhold information about negative outcomes in five clinically rigorous trials. Those clinical trials showed that Lidoderm was no more effective than a placebo in treating low back pain, carpal tunnel syndrome and neuropathic pain generally. Instead, Endo is alleged to have promoted demonstrably inferior and materially misleading studies to support the off-label use of the drug. The suit also alleged that the pharmaceutical giant improperly targeted physicians who were not likely to prescribe Lidoderm for the FDA-approved indication and shipped free Lidoderm samples to formulary executives to illegally induce them to provide preferential formulary treatment for the drug.
“The Texas Attorney General’s Office is very diligent in its prosecution of Medicaid fraud under the TMFPA,” Simmer said. “The state’s prosecutors led by Cynthia O’Keeffe and Kris Kennedy are very dedicated to this task. We thank them for their hard work and support of the role whistleblowers played in exposing this Lidoderm fraud.”
In addition to Simmer, the whistleblowers were also represented by Baron & Budd shareholder Andrew Miller. Baron & Budd’s whistleblower practice brings more than 33 years of combined experience investigating and prosecuting multiple precedent-setting fraud and abuse cases on behalf of whistleblowers and private payors.
ABOUT BARON & BUDD, P.C.
Baron & Budd, P.C. is among the largest and most accomplished plaintiffs’ law firms in the country. With more than 40 years of experience, Baron & Budd has the expertise and resources to handle complex litigation throughout the United States. As a law firm that takes pride in remaining at the forefront of litigation, Baron & Budd has spearheaded many significant cases for hundreds of entities and thousands of individuals. Since the firm was founded in 1977, Baron & Budd has achieved substantial national acclaim for its work on cutting-edge litigation, trying hundreds of cases to verdict and settling tens of thousands of cases in areas of litigation as diverse as dangerous pharmaceuticals and defective medical devices, asbestos and mesothelioma, environmental contamination, fraudulent banking practices, motor vehicles, employment, and other consumer fraud issues.
Baron & Budd, P.C.
Monica Cordova, 214-523-6633
Source: Baron & Budd